Literature DB >> 6433976

Tissue plasminogen activator: peptide analyses confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences.

G Pohl, M Källström, N Bergsdorf, P Wallén, H Jörnvall.   

Abstract

Tissue plasminogen activator, separated into variants I and II (differing in Mr by 2000-3000), was reduced and [14C]carboxymethylated. Fragments from cleavages with enzymes and cyanogen bromide (CNBr) were separated by reverse-phase high-performance liquid chromatography and subjected to sequence degradations. All seven CNBr fragments were purified and found to be compatible with the cDNA-derived amino acid sequence [Pennica, D., Holmes, W. E., Kohr, W. J., Harkins, R. N., Vehar, G. A., Ward, C. A., Bennett, W. F., Ylverton, E., Seeburg, P. H., Heynecker, H. L., Goeddel, D. V., & Collen, D. (1983) Nature (London) 301, 214-221]. Chemical characterization of 93% of the 527 residues recovered in 50 peptides confirmed the indirectly deduced primary structure of the protein. The tryptic peptide patterns from the two variants were found to differ for one peptide (T15). Since carbohydrate was present in this peptide for variant I and since a marked difference in chromatographic behavior for T15 was observed in variant II, we conclude that carbohydrate differences in this peptide (i.e., Asn-184 in the numbering system of the cDNA-derived amino acid sequence) are the explanation for the size differences between variants I and II. Carbohydrate was also found at two other positions in the protein, corresponding to Asn-117 and Asn-448. However, a fourth potential glycosylation site, Asn-218, is apparently not utilized for carbohydrate attachment. The enzyme is inactivated by diisopropyl phosphorofluoridate, which covalently modifies the serine residue corresponding to position 478, identifying this as the active site serine residue.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6433976     DOI: 10.1021/bi00311a020

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  19 in total

1.  Conservation of the kinaselike regulatory domain is essential for activation of the natriuretic peptide receptor guanylyl cyclases.

Authors:  K J Koller; F J de Sauvage; D G Lowe; D V Goeddel
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

Review 2.  N-glycoprotein macroheterogeneity: biological implications and proteomic characterization.

Authors:  Lucia F Zacchi; Benjamin L Schulz
Journal:  Glycoconj J       Date:  2015-12-05       Impact factor: 2.916

3.  The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator.

Authors:  T L Lindahl; P I Ohlsson; B Wiman
Journal:  Biochem J       Date:  1990-01-01       Impact factor: 3.857

4.  Localization of the binding site of tissue-type plasminogen activator to fibrin.

Authors:  A Ichinose; K Takio; K Fujikawa
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

Review 5.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

6.  Reduction of endogenous GRP78 levels improves secretion of a heterologous protein in CHO cells.

Authors:  A J Dorner; M G Krane; R J Kaufman
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

7.  Binding of tissue plasminogen activator to human aortic endothelial cells.

Authors:  M A Sanzo; S C Howard; A J Wittwer; H M Cochrane
Journal:  Biochem J       Date:  1990-07-15       Impact factor: 3.857

Review 8.  Tissue-type plasminogen activator as a therapeutic target in stroke.

Authors:  Iordanis Gravanis; Stella E Tsirka
Journal:  Expert Opin Ther Targets       Date:  2008-02       Impact factor: 6.902

9.  Cell-free synthesis of enzymically active tissue-type plasminogen activator. Protein folding determines the extent of N-linked glycosylation.

Authors:  N J Bulleid; R S Bassel-Duby; R B Freedman; J F Sambrook; M J Gething
Journal:  Biochem J       Date:  1992-08-15       Impact factor: 3.857

Review 10.  Carbohydrate analysis throughout the development of a protein therapeutic.

Authors:  Elizabeth Higgins
Journal:  Glycoconj J       Date:  2009-11-04       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.